Stockscreener 앱 받기
1.76
4.35%
-0.08
Pyxis Oncology Inc 주식(PYXS)의 최신 뉴스
Cancer drug developer Pyxis Oncology to join 2 November investor chats - Stock Titan
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff - The Spec
Pyxis Oncology Reports Increased Losses Amid Development Focus - MSN
Returns Recap: How Pyxis Oncology Inc. stock compares to growth peers2025 Fundamental Recap & Low Volatility Stock Recommendations - Улправда
Aug Action: Will Pyxis Oncology Inc. stock benefit from automationPortfolio Value Report & Precise Swing Trade Alerts - Улправда
Will Pyxis Oncology Inc. stock benefit from automationJuly 2025 Decliners & Consistent Income Trade Ideas - Улправда
Will Pyxis Oncology Inc. stock gain from government policiesJuly 2025 Final Week & Fast Entry Momentum Trade Alerts - Улправда
Is Pyxis Oncology Inc. stock a dividend growth opportunity2025 Key Lessons & Real-Time Chart Pattern Alerts - Улправда
The $537B Precision Pivot: Why Molecular Monitoring is the New Oncology Standard - The Globe and Mail
After-Hours Gainers: ALXO, GMED, ACRV, And Biotech Peers Rally On Trial Data And Earnings Updates - RTTNews
Pyxis Oncology, Inc.Common Stock (NQ: PYXS - FinancialContent
Is Pyxis Oncology Inc. stock recession proofHead and Shoulders Patterns & Create Your Free Watchlist Instantly - ulpravda.ru
PYXS Stock Price, Forecast & Analysis | PYXIS ONCOLOGY INC (NASDAQ:PYXS) - Chartmill
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
PYXS,RPTX Dividends - Finviz
Goosehead Insurance Inc 2OX Stock Analysis and ForecastMomentum Trading Signals & Exceptional Return Capital - earlytimes.in
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Is Pyxis Oncology Inc. stock positioned well for digital economyShort-Term Trading Alerts & Easy Tools to Analyze Your Investment Risk - bollywoodhelpline.com
Pyxis Oncology Inc. (PYXS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Short Interest in Pyxis Oncology, Inc. (NASDAQ:PYXS) Drops By 57.3% - MarketBeat
Pyxis Oncology Stock Plunge: A Buy Signal? - StocksToTrade
Pyxis Oncology Stock Slides 73% With A 7-Day Losing Spree - Trefis
Bear Alert: Is Pyxis Oncology Inc. stock a contrarian buy2025 Year in Review & Safe Entry Momentum Stock Tips - Улправда
How Pyxis Oncology Inc. stock compares to growth peersQuarterly Profit Summary & Weekly High Conviction Trade Ideas - Улправда
Pyxis Oncology Stock 6-Day Losing Spree: Stock Falls 71% - Trefis
Pyxis Oncology (NASDAQ:PYXS) Lowered to Sell Rating by Wall Street Zen - MarketBeat
HC Wainwright & Co. Maintains Pyxis Oncology (PYXS) Buy Recommendation - Nasdaq
RBC Capital Maintains Pyxis Oncology (PYXS) Outperform Recommendation - Nasdaq
Pyxis Oncology price target lowered to $5 from $8 at RBC Capital - MSN
Pyxis Oncology sees cash runway into 4Q26 - MSN
Pyxis Oncology stock price target raised to $7 by H.C. Wainwright - Investing.com Nigeria
RBC Capital Lowers Price Target for Pyxis Oncology (PYXS) to $5, Maintains Outperform Rating | PYXS Stock News - GuruFocus
Analysts Sound Alarm On Pyxis Oncology's Tiny Trial - Benzinga
RBC Cuts Price Target on Pyxis Oncology to $5 From $8, Keeps Outperform, Speculative Risk - marketscreener.com
Pyxis plummets following phase 1 data on candidate for head and neck cancer - MSN
Is Pyxis Oncology Inc. stock a contrarian buy2025 Trade Ideas & Risk Adjusted Buy/Sell Alerts - Улправда
Pyxis Oncology Sees Unusually High Options Volume (NASDAQ:PYXS) - Defense World
Pyxis Oncology reports positive data for head and neck cancer drug By Investing.com - Investing.com South Africa
Fed Meeting: Is Pyxis Oncology Inc. stock positioned well for digital economyMarket Trend Report & AI Enhanced Trade Execution Alerts - Улправда
Pyxis Oncology stock falls as RBC cuts price target on complex trial data - Investing.com Australia
Pyxis Oncology stock falls as RBC cuts price target on complex trial data By Investing.com - Investing.com South Africa
Pyxis Oncology reports positive data for head and neck cancer drug - Investing.com Nigeria
Pyxis Oncology Stock (PYXS) Opinions on Phase 1 Cancer Drug Data - Quiver Quantitative
Stock Traders Buy Large Volume of Pyxis Oncology Put Options (NASDAQ:PYXS) - MarketBeat
Pyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic Head and Neck Squamous Cell CarcinomaSlideshow (NASDAQ:PYXS) 2025-12-18 - Seeking Alpha
4.73%
0.92%
자본화:
|
볼륨(24시간):